Introduction
Recent studies have revealed that angiogenesis is essential for growth, persistence, and metastasis of solid tumors. Angiogenesis is controlled by a local balance between stimulators and inhibitors of growth of new vessels and is suppressed under normal physiological conditions (Fidler and Ellis, 1994; Folkman, 1995; Hanahan and Folkman, 1996) . Several endogenous negative regulators of angiogenesis, including thrombospondins, angiostatin, endostatin, and glioma-derived angiogenesis inhibitory factor (GD ± AIF) are considered to play signi®cant roles in maintaining the quiescence of vessels. For cancer to progress, tumor cells must undergo genetic changes that lead to the angiogenic phenotype in order to obtain a blood supply for their growth.
Glioblastomas are among the most dramatically neovascularized neoplasms; progression of a glioma to its more malignant form of glioblastoma is usually associated with striking neovascularization, evidenced by vasoproliferation, altered endothelial cell cytology, and endothelial cell hyperplasia. Hence, gliomas and glioblastomas can serve as a model system for investigating the relationship between genetic alterations and angiogenesis. Among the genetic changes found so far in these tumors, alteration of p53 appears to play a signi®cant role in progression; neovascularization may be a direct consequence of inactivation of p53 (van Meir et al., 1994a) , possibly due to loss of transactivation of one or more genes regulated by p53 . For example, loss of wild-type p53 results in reduced expression of the thrombospondin 1 gene and can switch ®broblasts to the more angiogenic phenotype (Dameron et al., 1994) .
The p53 tumor suppressor is the most frequently altered gene in human cancers (Hollstein et al., 1991) . Its protein product, which binds DNA in a sequencespeci®c manner, regulates transcription of genes containing its consensus binding site (El-Deiry et al., 1992; Tokino et al., 1994) . Therefore, if one is to investigate the biological functions of p53 including inhibition of angiogenesis, it is important to identify p53-target genes. We approached this challenge by attempting to isolate cosmid clones containing functional' p53-binding sites (termed p53-tagged sites) and screening candidate genes in the vicinity of those sites. In this manner we previously isolated GML, a mediator of p53 signals that is likely to play a signi®cant role in the apoptosis induced by anti-cancer drugs (Furuhata et al., 1996; Kimura et al., in press) .
We report here a novel brain-speci®c p53-target gene that is a strong candidate as an inhibitor of the angiogenesis that accompanies progression of gliaderived tumors.
Results

Isolation of cDNA
We screened a human cosmid library using a known p53-tagged site (clone p53-31; Figure 1a ) as a probe and isolated one cosmid, designated p53-cos170. Sequencing of genomic DNA contained in p53-cos170, and subsequent computer analysis predicted four potential exons. We synthesized oligonucleotides corresponding to these possible exons and performed exon-connection experiments (Fearon et al., 1990) . Two of the predicted exons were connected by RT ± PCR when we used brain mRNAs as a template, and we designated the 453 bp exon-connected product 170E1. To con®rm whether expression of this gene was regulated by p53, glioblastoma cell line T98G, which has lost one allele and contains p53 mutation (Met 237 Ile) in the remaining allele (van Meir et al., 1994b) , was transiently transfected with an expression vector containing either wild-type or mutant p53. Reverse-transcriptase PCR (RT ± PCR) analysis revealed that this transcript was expressed in T98G cells transfected with wild-type p53 but absent from those with mutant p53 or parental cells (Figure 1b) , indicating that transcription of this gene was inducible by wild-type p53.
We screened a human fetal-brain cDNA library (1.0610 6 plaques) using 170E1 as a probe and isolated 40 cDNA clones. The alignment of three representative cDNA sequences revealed a 5535 bp transcript containing an open reading frame of 4755 bp. Figure 2a shows the predicted 1584-amino acid coding sequence of this gene de®ned by (i) a stop codon present in the reading frame 5' to the putative ATG start site; (ii) multiple stop codons in the noncoding frames 3' to the start site; and (iii) multiple stop codons in all three reading frames that lay 3' to the putative terminal TAG stop codon. However, we assumed that the cDNA clone lacked some 5' non-coding sequence, since Northern blot analysis revealed a transcript of about 6.5 kb in fetal and adult brain (Figure 2b ). Expression of this gene was speci®c to brain tissues. The nucleotide and predicted amino acid sequences have been deposited in DDBJ, EMBL and GenBank (accession No AB005297).
Structural analysis of the BAI1 protein
A hydropathy plot analysis (Kyte and Doolittle, 1982) of the predicted protein identi®ed seven hydrophobic segments within the C-terminal portion of the molecule and indicated that N-terminal methionine was followed by a hydrophobic signal sequence. This result suggests that the gene product is a multispanning membrane protein, with a possible extracellular part of nearly 930 amino acids, a 233-amino-acid region that passes the membrane seven times, and a cytoplasmic region of about 400 amino acids (Figure 3a) . Although the amino acid sequence of the seven-span transmembrane region shows no homology with the corresponding region of classical G-protein coupled receptors (Baldwin, 1993) , it possesses 23% identity to CD97, a leukocyte-activating antigen and a member of the secretin receptor superfamily (Hamann et al., 1995) .
The extracellular region revealed signi®cant homology to the TSP-type 1 repeats that are known to bind to several proteins including laminin, ®bronectin, heparin, sulfatide and heparin sulfate proteoglycan (Lawler and Hynes, 1986; Bornstein, 1992; Robert, 1996) (Figure 3b ). The deduced protein contains ®ve TSP-type 1 repeats while TSP1 and TSP2 each contain three. Peptides corresponding to TSP-type 1 repeats reportedly inhibit experimental angiogenesis induced by bFGF (Tolsma et al., 1993) . Among the ®ve dierent TSP genes identi®ed to date, only TSP1 and TSP2 that contain the type 1 repeats inhibit angiogenesis. A search for established consensus sites within the extracellular domain of this predicted protein also revealed the presence of a single Arg ± Gly ± Asp (RGD) motif, a potential recognition sequence for binding integrins (d 'Souza et al., 1991; Haas and Plow, 1994) . From the sequence similarities noted above, we assumed that the product of the novel gene could inhibit angiogenesis, and on that basis we designated it BAI1, brain-speci®c angiogenesis inhibitor.
BAI1 expression in glioblastoma cell lines
To investigate a possible role of BAI1 in development and/or progression of glioblastoma, we examined its expression in glioblastoma cell lines by means of an RT ± PCR experiment using RNA from cultured astrocytes as a control. Among the nine glioblastoma cell lines examined, BAI1 expression was lost in six (A172, T98G, U87MG, DBTRG05MG, SW1783 and U373MG) and signi®cantly reduced in the other two (SW1088 and YKG1), as shown in Figure 4 .
In vivo antiangiogenic eect by BAI1
To evaluate whether the BAI1 gene product could inhibit angiogenesis in vivo, we subsequently constructed two plasmid clones designed to express GST-BAI1 fusion proteins, GST-BAI1-type 1A and GST-BAI1-type 1B. GST-BAI1-type 1A and GST-BAI1-type 1B contain the middle three and the last three TSP-type 1 repeats of BAI1, respectively. The EVA copolymer pellet containing the recombinant proteins were implanted in rat corneas and their ability to recruit new blood vessels from the limbas was assessed. The recombinant protein GST-BAI1-type 1A effectively inhibited in vivo neovascularization induced by bFGF in corneas of all ®ve independent rats, whereas structurally similar GST-BAI1-type 1B had lower activity ( Figure 5 ).
Discussion
We followed a strategy to identify p53-target genes through cloning of candidates for`functional' p53-binding sites (p53-tagged sites) from the human genome, and successfully isolated a novel p53-inducible gene, BAI1, that is speci®cally expressed in brain. Transcriptional activation of BAI1 following introduction of wild-type p53 into the tumor cell line is likely to be a direct eect of wild-type p53 protein, because we identi®ed at least one`functional' p53-binding sequence within a cosmid carrying a part of the BAI1 gene. Genomic structure of BAI1 gene were partially determined, which revealed that BAI1 gene spanned at least 80 kb and consisted of more than 28 exons and also that the p53-binding site was localized in the intron 9 (unpublished data).
A number of investigators have reported correlation between p53 alterations and progression of brain tumors. As far as is known, p53 is the most frequently altered gene in human glioblastomas, and its loss is thought to stimulate neovascularization. Moreover, in published experiments a glioblastoma cell line LN ± Z308, upon introduction of wild-type, but not mutant, p53, produced a secretory inhibitor of capillary endothelial cell migration designated glioma-derived angiogenesis inhibitory factor (GD ± AIF) (van Meir et al., 1994a) . We consider BAI1 to be a strong candidate for a signi®cant role in tumor suppression of glioblastoma, on the basis of the following observations: (i) BAI1 transcript was induced by wild-type p53, and predominantly recognized in brain; (ii) BAI1 expression was absent or signi®cantly reduced in eight of the nine glioblastoma cell lines examined; (iii) Among the ®ve dierent TSP genes identi®ed to date, only TSP1 and TSP2 that are thought to inhibit the angiogenesis contain the type 1 repeats. BAI1 also contains the ®ve TSP-type 1 repeats in its extracellular domain; (iv) A recombinant protein containing the TSP-type 1 repeats of BAI1 inhibited in vivo angiogenesis in rat cornea. Although one peptide corresponding to the last three repeats had lower activity, the similar dierence was also reported in the experiments using synthetic peptides derived from thrombospondin 1, in which two of the three peptides corresponding the T98G  A172  U87MG  U118MG  U373MG  SW1088  SW1783  DBTRG05MG   YKG1   BAI1   G3PDH 453 bp 983 bp Figure 4 RT ± PCR analysis of BAI1 mRNA expression in a panel of cultured astrocytes and nine glioblastoma cell lines under semiquantitative conditions. Expression was determined by RT ± PCR ampli®cation using the same methods and primers as described for Figure 1b . The PCR products were separated by electrophoresis on a 2% agarose gel and their sizes (in bp) are shown on the right. PCR reactions were performed at least twice to con®rm the results. The integrity of the RNA template was controlled through ampli®cation of a G3PDH transcript which revealed similar signals in all samples TSP-type-1 repeat could suppress in vivo neovascularization while one was inactive (Tolsma et al., 1993) . The dierent activities may be due to dierences in peptide structure and solubility, or may indicate the second type 1 repeat contain the signi®cant domain to suppress angiogenesis. This discrepancy might be explained by dierential sensitivity of these two fusion proteins to proteases encountered in vivo in the pellets. It is, however, unclear whether BAI1 is a candidate for the GD ± AIF reported by van Meir et al. (1994a) , since we do not know if BAI1 can be enzymatically cleaved and secreted as a soluble form. Our results indicate, however, that the BAI1 gene product is a membrane protein that is likely to be a potent inhibitor of angiogenesis in brain and to play a signi®cant role as a mediator of the p53 signal in suppression of glioblastoma.
Materials and methods
BAI1 cDNA screening
A DNA fragment (clone p53-31 in Tokino et al., 1994) containing a p53-tagged site, radiolabeled and used as a probe to screen a human cosmid library (Tokino et al., 1991) , allowed us to isolate a clone which we named p53-cos170. We subsequently determined genomic DNA sequences contained in the cosmid, using the 377 ABI autosequencer (Perkin-Elmer) and a protocol described elsewhere (Ishikawa et al., 1997) . We searched for possible exons with two exon-prediction computer programs, Grail2 and Hexon (Solovyev et al., 1994; Xu et al., 1995) , and obtained several candidate exons. To investigate whether these DNA fragments are transcribed, we performed an exon-connection experiment by RT ± PCR using primers E1S and E1A, and con®rmed that two of the predicted exons were connected. We designated the connected cDNA fragment 170E1 and used it as a probe for Northern hybridization and for screening a human fetal-brain cDNA library (Stratagene).
RT ± PCR analysis
T98G, a glioblastoma cell line, were transiently transfected with an expression vector, either p53-wt or p53-273 . One million cells were plated in 25 cm 2 asks 24 h before transfection. Five micrograms of plasmid DNA and 25 ml of Lipofectin (Gibco-BRL) were used for each transfection. The preparation of cDNA was performed as described elsewhere (Fidler and Ellis, 1994) . The RT ± PCR exponential phase was determined on 20 ± 30 cycles to allow quantitative comparisons among the cDNAs developed from identical reactions. Each PCR experiment was carried out using cDNA generated from 0.2 mg total RNA. The PCR solutions have been described previously (Han et al., 1995) ; all reactions involved a 948C, 2 min initial denaturation step followed by 30 cycles (for 170E1) or 25 cycles (for p21/WAF1 and G3PDH) at 948C for 30 s, 55 ± 598C for 1 min, and 728C for 90 s, on a GeneAmp PCR system 9600 (Perkin-Elmer). Primer sequences were as follows: E1S, 5'-ACTCATCCTGC-GACGGTGTG-3' and E1A, 5'-TCCCTCAGGTCCTT-CATGCG-3' for 170E1; W1S, 5'-GTTCCTTGTG GAGCCGGAGC-3' and W2A, 5'-GGTACAAGACAGT-GACAGGTC-3' for p21/WAF1; HGS, 5'-TGAAGGTCG-GAGTCAACGGATTTGGT-3' and HGA, 5'-CATGT GGGCCATGAGGTCCACCAC-3' for G3PDH. The PCR products were separated by electrophoresis on 2% GTG agarose gels.
Northern blot analysis
Northern blots, containing in each lane 2 mg poly(A) + RNA from one of 20 dierent normal human tissues, were purchased from Clontech. The blots were hybridized with a random-primed 32 P-labeled DNA probe corresponding to nucleotides 2013-2465 of the BAI1 cDNA, according to the manufacturer's instructions. The blots were washed with 0.16SSC/0.1% SDS at 508C and exposed for autoradiography at 7808C for 7 days.
Cell lines
Nine glioblastoma cell lines were used in this study: A172, T98G and YKG1 were purchased from HSRRB (Tokyo); U87MG, U118MG, U373MG, SW1088, SW1783 and a b c d e Figure 5 The eect of the recombinant proteins derived from BAI1 on in vivo neovascularization induced by bFGF in rat cornea. EVA pellets were formulated as described in the Materials and methods and implanted into cornea of rats. Seven days later vessels in the region of the pellet implant were photographed. Pellets contained (a) PBS; (b) bFGF; (c) bFGF+GST; (d) bFGF+GST-BAI1-type1A; (E) bFGF+GST-BAI1-type1B DBTRG05MG were from ATCC. Primary human astrocytes were purchased from Iwaki (Tokyo). All cells were cultured under conditions recommended by their respective depositors. RNA extraction and quantitative RT ± PCR experiments were carried out as described above.
Plasmid construction
We generated two fusion constructs of BAI1-glutathione Stransferase in pGEX-5X-2 (Pharmacia). The GST-BAI1-type 1A and GST-BAI1-type 1B constructs contained cDNA fragments corresponding respectively to amino acids 340 ± 495 of BAI1 and 386 ± 568 of BAI1. The fusion proteins expressed in Escherichia coli were puri®ed from insoluble bacterial pellets according to the manufacturer's instructions (Pharmacia).
In vivo neovascularization assay
In corneal pocket assay, slow-release ethylene-vinylacetate (EVA) copolymer pellets containing 50 ng of bFGF with 2 mM of control GST, GST-BAI1-type 1A, and GST-BAI1-type 1B proteins were prepared and implanted in the cornea of male SD rats (200 ± 400 g). Neovascularization was assessed under a microscope at 5 and 7 days, and representative responses were photographed. Five rats were used to assess the eect of each fusion-protein.
